Smoking and RA: A Deadly Combination (CME/CE)

(MedPage Today) -- Medium-term mortality doubled in smokers with rheumatoid arthritis
Source: MedPage Today Geriatrics - Category: Geriatrics Source Type: news

Related Links:

ConclusionCollectively, SP can block the loss of therapeutic potential of MSCs by preserving their proliferative and paracrine potential. This study indicates the potential of SP as a supplement in stem cell culture for therapy.
Source: Molecular and Cellular Toxicology - Category: Cytology Source Type: research
Conclusion: Despite low disease activity, saliva TNF-α and caspase-1 levels were found to be significantly higher in the pSjS group, which may suggest a possible advantage of local anticytokine treatments in selected cases. PMID: 29914252 [PubMed]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Patients with rheumatoid arthritis (RA) have an increased risk of coronary artery disease (CAD) above the baseline. Baicalin possesses beneficial effects against both RA and CAD, but little is know on its clin...
Source: Lipids in Health and Disease - Category: Lipidology Authors: Tags: Research Source Type: research
Rheumatoid arthritis (RA) patients of South Asian origin now have extra help in living with a painful and incurable condition – thanks to anew educational video that encourages them to understand when and why they need to move from standard treatment to treatment with a biologic.
Source: Rheumatology - Category: Rheumatology Source Type: research
In an open-label clinical trial, Jabbari and colleagues demonstrated clinical efficacy of the small molecule JAK1,3 inhibitor tofacitinib in 12 patients with moderate-to-severe alopecia areata (AA), a disease that results from autoimmune attack on the hair follicles with resulting significant hair loss. Tofacitinib, which has previously been approved for treatment of rheumatoid arthritis, halted hair loss and allowed considerable regrowth in 11 of these patients without serious adverse effects. Although the therapy is non-curative, as evidenced by relapse after treatment cessation, tofacitinib is a promising therapy for th...
Source: Journal of Investigative Dermatology - Category: Dermatology Tags: Editorial Source Type: research
Authors: Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE Abstract INTRODUCTION: Interleukin-6 (IL-6) is well-known for its pro-inflammatory properties, has been proven to target a wide range of cells in the joint and has been implicated in extra-articular and articular manifestations in rheumatoid arthritis (RA). Tocilizumab (TCZ) is now widely used in patients with active RA and a number of additional agents that target the IL-6 pathways are under development, including sirukumab (SRK). Areas covered: SRK is a IgG1κ human anti-IL-6 monoclonal antibody which binds to IL-6 and prevents IL-6 mediated do...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
-- Rheumatoid arthritis is a chronic disease that causes considerable pain in joints. At some point, most people with RA develop pain in the ankle and foot. While there is no cure, the American Academy of Orthopaedic Surgeons says there are things...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Disease-modifying antirheumatic drugs (DMARDs) reduce the risk of developing rheumatoid arthritis (RA) in patients with early undifferentiated arthritis, researchers from France report.Reuters Health Information
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Rheumatology News Source Type: news
Conclusion  Although there is paucity in evidence for the use of AS in the wrists of patients with JIA, studies suggest it to be safe and effective, and could be applied to patients with refractive JIA. It is possible that early identification of patients suffering from JIA with extensive joint destruction and little symptoms could benefit from AS, delaying joint destruction and preserving function. PMID: 29922493 [PubMed]
Source: Hand Surgery - Category: Surgery Authors: Tags: J Wrist Surg Source Type: research
The IL-6 receptor antagonist tocilizumab has been shown to attenuate the proatherogenic lipoprotein a [Lp(a)] in rheumatoid arthritis. We evaluated if a single dose of tocilizumab reduced Lp(a) in patients with non-ST-elevation myocardial infarction (NSTEMI).
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Short communication Source Type: research
More News: Arthritis | Geriatrics | Rheumatoid Arthritis | Rheumatology | Smokers